ROCHE HOLDING AG (1ROG.MI) Stock Price & Overview

BIT:1ROG • CH1499059983

Current stock price

342.8 EUR
-18.6 (-5.15%)
Last:

The current stock price of 1ROG.MI is 342.8 EUR. Today 1ROG.MI is down by -5.15%. In the past month the price increased by 0.07%.

1ROG.MI Key Statistics

1-Month Range309 - 402
Current 1ROG.MI stock price positioned within its 1-month range.
Market Cap
277.411B
P/E
16.14
Fwd P/E
15.66
EPS (TTM)
21.24
Dividend Yield
3.09%

1ROG.MI Stock Performance

Today
-5.15%
1 Week
-10.99%
1 Month
+0.07%
3 Months
+27.43%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1ROG.MI Stock Chart

ROCHE HOLDING AG / 1ROG Daily stock chart

1ROG.MI Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to 1ROG.MI.


Chartmill TA Rating
Chartmill Setup Rating

1ROG.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 1ROG.MI. Both the health and profitability get an excellent rating, making 1ROG.MI a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1ROG.MI Earnings

On January 29, 2026 1ROG.MI reported an EPS of 8.53 and a revenue of 30.57B. The company missed EPS expectations (-3.53% surprise) and missed revenue expectations (-3.25% surprise).

Next Earnings DateApr 23, 2026
Last Earnings DateJan 29, 2026
PeriodQ4 / 2025
EPS ReportedCHF8.53
Revenue Reported30.572B
EPS Surprise -3.53%
Revenue Surprise -3.25%

1ROG.MI Forecast & Estimates

27 analysts have analysed 1ROG.MI and the average price target is 407.15 EUR. This implies a price increase of 18.77% is expected in the next year compared to the current price of 342.8.

For the next year, analysts expect an EPS growth of 3.06% and a revenue growth 1.15% for 1ROG.MI


Analysts
Analysts70.37
Price Target407.15 (18.77%)
EPS Next Y3.06%
Revenue Next Year1.15%

1ROG.MI Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

1ROG.MI Financial Highlights

Over the last trailing twelve months 1ROG.MI reported a non-GAAP Earnings per Share(EPS) of 21.24. The EPS increased by 4.41% compared to the year before.


Income Statements
Revenue(TTM)61.52B
Net Income(TTM)12.88B
Industry RankSector Rank
PM (TTM) 20.94%
ROA 12.79%
ROE 38.1%
Debt/Equity 0.85
Chartmill High Growth Momentum
EPS Q2Q%-0.47%
Sales Q2Q%-0.24%
EPS 1Y (TTM)4.41%
Revenue 1Y (TTM)1.69%

1ROG.MI Ownership

Ownership
Inst Owners41.71%
Shares809.25M
Float688.92M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About 1ROG.MI

Company Profile

1ROG logo image Roche Holding AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Basel, Basel-Stadt and currently employs 112,774 full-time employees. The company went IPO on 2001-05-04. Roche Holding AG (Roche) is a research-based healthcare company. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Company Info

IPO: 2001-05-04

ROCHE HOLDING AG

Grenzacherstr. 124

Basel BASEL-STADT CH

Employees: 112774

1ROG Company Website

1ROG Investor Relations

Phone: 41616881111

ROCHE HOLDING AG / 1ROG.MI FAQ

Can you describe the business of ROCHE HOLDING AG?

Roche Holding AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Basel, Basel-Stadt and currently employs 112,774 full-time employees. The company went IPO on 2001-05-04. Roche Holding AG (Roche) is a research-based healthcare company. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.


What is the current price of 1ROG stock?

The current stock price of 1ROG.MI is 342.8 EUR. The price decreased by -5.15% in the last trading session.


Does 1ROG stock pay dividends?

ROCHE HOLDING AG (1ROG.MI) has a dividend yield of 3.09%. The yearly dividend amount is currently 0.


How is the ChartMill rating for ROCHE HOLDING AG?

1ROG.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the analyst forecast for 1ROG.MI stock?

27 analysts have analysed 1ROG.MI and the average price target is 407.15 EUR. This implies a price increase of 18.77% is expected in the next year compared to the current price of 342.8.


Can you provide the sector and industry classification for ROCHE HOLDING AG?

ROCHE HOLDING AG (1ROG.MI) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the PE ratio for 1ROG stock?

The PE ratio for ROCHE HOLDING AG (1ROG.MI) is 16.14. This is based on the reported non-GAAP earnings per share of 21.24 and the current share price of 342.8 EUR.